Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health reported interim Phase 1 results for a dual Lassa fever–rabies vaccine in Nature Medicine. The adjuvanted inactivated rabies virus-vectored Lassa vaccine was reported as safe in healthy adults and induced immune responses against both pathogens. The study, led by principal investigator Justin Ortiz, described the rationale for combining two global health priorities into one product to potentially streamline vaccination in regions where both diseases are endemic. Investigators highlighted that Lassa virus is recognized by WHO as a public health threat, with case undercounting due to surveillance limitations. With Lassa infections cited as reaching about 300,000 cases annually and with high fatality risk, the authors noted particular vulnerability in pregnancy. They also reported that rabies remains almost invariably fatal once symptoms develop, underscoring the goal of assessing a combined immunization approach.